Eventide Asset Management’s enGene Therapeutics ENGN Stock Holding History
Bought
Maintained
Sold
Other funds holding ENGN
BCM
SL
ACA
Eventide Asset Management's ENGN Position: Q3 2026 in Review
Eventide Asset Management opened a new position in enGene Therapeutics (ENGN) in Q3 2026: 3,406,023 shares worth $6.81M. The stake represents 0.1% of the portfolio and ranks #172 among its holdings. This is a return to the name: Eventide Asset Management previously reported a position in ENGN as recently as Q4 2025.
Eventide Asset Management first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.58M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.
- Eventide Asset Management held 3,406,023 shares of enGene Therapeutics worth $6.81M as of Q3 2026.
- enGene Therapeutics was a new Eventide Asset Management position in Q3 2026.
- enGene Therapeutics made up 0.1% of Eventide Asset Management's portfolio in Q3 2026, its #172 holding.
- Eventide Asset Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
- Eventide Asset Management's enGene Therapeutics position peaked at $8.58M in Q4 2025.
- 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.
Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.